Novartis has cash for a big pharma deal—but here’s why it’s not buying

Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested in one, according to its chief executive Vasant Narasimhan. That’s because the bigger deals have historically not paid off in the pharmaceutical sector. “They significantly disrupt R&D; synergies don’t materialize,” he […]